Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 6 | 2009 | 57 | 1.190 |
Why?
|
| Respiration, Artificial | 5 | 2016 | 98 | 1.000 |
Why?
|
| Pneumonia, Ventilator-Associated | 3 | 2013 | 11 | 0.990 |
Why?
|
| Pneumonia, Bacterial | 5 | 2006 | 33 | 0.950 |
Why?
|
| Asthma | 8 | 2009 | 261 | 0.830 |
Why?
|
| Anti-Bacterial Agents | 5 | 2006 | 324 | 0.650 |
Why?
|
| Intensive Care Units | 7 | 2013 | 121 | 0.600 |
Why?
|
| Tidal Volume | 1 | 2016 | 8 | 0.500 |
Why?
|
| Lung Injury | 1 | 2016 | 67 | 0.470 |
Why?
|
| Lung | 1 | 2016 | 263 | 0.430 |
Why?
|
| Intubation, Intratracheal | 1 | 2013 | 56 | 0.370 |
Why?
|
| Delirium | 2 | 2018 | 14 | 0.350 |
Why?
|
| Critical Care | 4 | 2010 | 108 | 0.310 |
Why?
|
| Ranitidine | 1 | 2009 | 3 | 0.300 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2009 | 3 | 0.300 |
Why?
|
| Peptic Ulcer | 1 | 2009 | 5 | 0.300 |
Why?
|
| Health Status | 2 | 2002 | 355 | 0.300 |
Why?
|
| Phospholipases A | 3 | 2005 | 31 | 0.280 |
Why?
|
| Hospital Mortality | 1 | 2010 | 197 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 3 | 2010 | 395 | 0.260 |
Why?
|
| Institutional Practice | 1 | 2006 | 1 | 0.250 |
Why?
|
| Humans | 24 | 2018 | 32282 | 0.230 |
Why?
|
| Critical Illness | 3 | 2018 | 87 | 0.230 |
Why?
|
| Community-Acquired Infections | 1 | 2005 | 33 | 0.220 |
Why?
|
| Acetates | 1 | 2005 | 14 | 0.220 |
Why?
|
| Indoles | 1 | 2005 | 65 | 0.220 |
Why?
|
| Hospital Costs | 1 | 2004 | 48 | 0.200 |
Why?
|
| Attention | 1 | 2004 | 84 | 0.200 |
Why?
|
| Ribonucleases | 1 | 2003 | 7 | 0.200 |
Why?
|
| Sputum | 1 | 2003 | 17 | 0.190 |
Why?
|
| Blood Proteins | 1 | 2003 | 19 | 0.190 |
Why?
|
| Saliva | 1 | 2003 | 39 | 0.190 |
Why?
|
| Length of Stay | 1 | 2004 | 321 | 0.190 |
Why?
|
| Ventilators, Mechanical | 1 | 2002 | 6 | 0.190 |
Why?
|
| Inflammation Mediators | 1 | 2003 | 96 | 0.190 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2002 | 116 | 0.170 |
Why?
|
| Health Care Costs | 1 | 2002 | 122 | 0.170 |
Why?
|
| Trachea | 3 | 2007 | 53 | 0.170 |
Why?
|
| Health Services | 1 | 2000 | 40 | 0.160 |
Why?
|
| Haloperidol | 1 | 2018 | 15 | 0.140 |
Why?
|
| Equipment Contamination | 2 | 2013 | 13 | 0.140 |
Why?
|
| Dopamine Antagonists | 1 | 2018 | 31 | 0.140 |
Why?
|
| Thiazoles | 1 | 2018 | 36 | 0.140 |
Why?
|
| Antipsychotic Agents | 1 | 2018 | 30 | 0.140 |
Why?
|
| Piperazines | 1 | 2018 | 60 | 0.140 |
Why?
|
| Aged | 5 | 2018 | 10263 | 0.140 |
Why?
|
| Eosinophils | 3 | 2009 | 32 | 0.130 |
Why?
|
| Incidence | 2 | 2013 | 1241 | 0.130 |
Why?
|
| Treatment Outcome | 4 | 2010 | 3416 | 0.130 |
Why?
|
| Retrospective Studies | 3 | 2013 | 3626 | 0.130 |
Why?
|
| Female | 12 | 2018 | 19945 | 0.120 |
Why?
|
| Positive-Pressure Respiration | 1 | 2016 | 14 | 0.120 |
Why?
|
| Male | 11 | 2018 | 19441 | 0.120 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 2240 | 0.120 |
Why?
|
| Prognosis | 3 | 2010 | 1534 | 0.110 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2005 | 59 | 0.110 |
Why?
|
| Treatment Failure | 2 | 2018 | 165 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2010 | 1425 | 0.100 |
Why?
|
| Administration, Inhalation | 2 | 2005 | 43 | 0.100 |
Why?
|
| Double-Blind Method | 4 | 2018 | 565 | 0.100 |
Why?
|
| Monitoring, Physiologic | 2 | 2010 | 77 | 0.100 |
Why?
|
| Catheterization | 2 | 2007 | 55 | 0.100 |
Why?
|
| Equipment Design | 1 | 2013 | 178 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2009 | 1840 | 0.090 |
Why?
|
| Adult | 7 | 2010 | 9259 | 0.090 |
Why?
|
| Risk Factors | 2 | 2013 | 3934 | 0.090 |
Why?
|
| Central Venous Pressure | 1 | 2010 | 5 | 0.080 |
Why?
|
| Blood Pressure Determination | 1 | 2010 | 106 | 0.080 |
Why?
|
| Ultrasonography, Doppler | 1 | 2010 | 23 | 0.080 |
Why?
|
| Fluid Therapy | 1 | 2010 | 25 | 0.080 |
Why?
|
| United States | 2 | 2013 | 4072 | 0.070 |
Why?
|
| Anti-Ulcer Agents | 1 | 2009 | 4 | 0.070 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2009 | 14 | 0.070 |
Why?
|
| Area Under Curve | 1 | 2009 | 90 | 0.070 |
Why?
|
| Arachidonic Acid | 1 | 2009 | 40 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 128 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2009 | 141 | 0.070 |
Why?
|
| Probability | 1 | 2009 | 155 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2009 | 174 | 0.070 |
Why?
|
| Age Distribution | 1 | 2009 | 194 | 0.070 |
Why?
|
| Reference Values | 1 | 2009 | 238 | 0.070 |
Why?
|
| Middle Aged | 6 | 2018 | 11851 | 0.070 |
Why?
|
| Phospholipases A2 | 2 | 2005 | 25 | 0.070 |
Why?
|
| Glottis | 1 | 2007 | 7 | 0.070 |
Why?
|
| Oropharynx | 1 | 2007 | 9 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2010 | 907 | 0.070 |
Why?
|
| Time Factors | 1 | 2013 | 2205 | 0.070 |
Why?
|
| Mucous Membrane | 1 | 2007 | 27 | 0.070 |
Why?
|
| Survival Rate | 1 | 2010 | 893 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 651 | 0.070 |
Why?
|
| Logistic Models | 1 | 2009 | 743 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 773 | 0.060 |
Why?
|
| Microbiological Techniques | 1 | 2006 | 1 | 0.060 |
Why?
|
| Pulmonary Surfactants | 2 | 2004 | 17 | 0.060 |
Why?
|
| Policy Making | 1 | 2006 | 17 | 0.060 |
Why?
|
| Bronchoscopy | 1 | 2006 | 54 | 0.060 |
Why?
|
| Bronchoconstriction | 1 | 2005 | 3 | 0.060 |
Why?
|
| Bronchial Provocation Tests | 1 | 2005 | 6 | 0.060 |
Why?
|
| Adolescent | 1 | 2013 | 3519 | 0.060 |
Why?
|
| Skin Tests | 1 | 2005 | 13 | 0.060 |
Why?
|
| Forced Expiratory Volume | 1 | 2005 | 81 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2005 | 94 | 0.050 |
Why?
|
| Phosphatidylglycerols | 1 | 2004 | 8 | 0.050 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2005 | 88 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 504 | 0.050 |
Why?
|
| Allergens | 1 | 2004 | 14 | 0.050 |
Why?
|
| Nursing Assessment | 1 | 2004 | 12 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2009 | 823 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2004 | 106 | 0.050 |
Why?
|
| Quinine | 1 | 2003 | 4 | 0.050 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2003 | 3 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2005 | 2316 | 0.050 |
Why?
|
| Muscle Relaxants, Central | 1 | 2003 | 10 | 0.050 |
Why?
|
| Leukotriene A4 | 1 | 2003 | 1 | 0.050 |
Why?
|
| Eosinophil Granule Proteins | 1 | 2003 | 2 | 0.050 |
Why?
|
| Food, Formulated | 1 | 2003 | 13 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 717 | 0.050 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2003 | 43 | 0.050 |
Why?
|
| Health Maintenance Organizations | 1 | 2002 | 16 | 0.050 |
Why?
|
| Respiratory Insufficiency | 2 | 2018 | 60 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2002 | 69 | 0.040 |
Why?
|
| Self Concept | 1 | 2000 | 45 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2002 | 757 | 0.040 |
Why?
|
| Health Expenditures | 1 | 2000 | 66 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 3900 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2000 | 245 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2002 | 853 | 0.040 |
Why?
|
| Age Factors | 1 | 2002 | 1179 | 0.040 |
Why?
|
| Shock | 1 | 2018 | 34 | 0.030 |
Why?
|
| Sterilization | 1 | 1996 | 3 | 0.030 |
Why?
|
| Disinfectants | 1 | 1996 | 4 | 0.030 |
Why?
|
| Chlorhexidine | 1 | 1996 | 7 | 0.030 |
Why?
|
| Quality of Life | 1 | 2000 | 964 | 0.030 |
Why?
|
| Blood Pressure Monitors | 1 | 2010 | 4 | 0.020 |
Why?
|
| Electronic Mail | 1 | 2010 | 20 | 0.020 |
Why?
|
| Physician's Role | 1 | 2010 | 41 | 0.020 |
Why?
|
| Focus Groups | 1 | 2010 | 123 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 171 | 0.020 |
Why?
|
| Observer Variation | 1 | 2010 | 96 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2010 | 77 | 0.020 |
Why?
|
| Catheterization, Central Venous | 1 | 2010 | 62 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 556 | 0.020 |
Why?
|
| Group IV Phospholipases A2 | 1 | 2009 | 6 | 0.020 |
Why?
|
| Interleukin-5 | 1 | 2009 | 7 | 0.020 |
Why?
|
| Acyltransferases | 1 | 2009 | 18 | 0.020 |
Why?
|
| Caspases | 1 | 2009 | 41 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2009 | 138 | 0.020 |
Why?
|
| Multiple Trauma | 1 | 2007 | 41 | 0.020 |
Why?
|
| ROC Curve | 1 | 2005 | 169 | 0.010 |
Why?
|
| Trauma Centers | 1 | 2005 | 84 | 0.010 |
Why?
|
| Surface Tension | 1 | 2004 | 6 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2004 | 9 | 0.010 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2004 | 15 | 0.010 |
Why?
|
| Phosphatidylcholines | 1 | 2004 | 29 | 0.010 |
Why?
|
| Muscle Cramp | 1 | 2003 | 4 | 0.010 |
Why?
|
| Group II Phospholipases A2 | 1 | 2003 | 5 | 0.010 |
Why?
|
| Emulsions | 1 | 2003 | 8 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2003 | 19 | 0.010 |
Why?
|
| gamma-Linolenic Acid | 1 | 2003 | 11 | 0.010 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2003 | 32 | 0.010 |
Why?
|
| Erythrocyte Transfusion | 1 | 2003 | 27 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 883 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2003 | 50 | 0.010 |
Why?
|
| Leg | 1 | 2003 | 67 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2003 | 129 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2003 | 100 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2003 | 276 | 0.010 |
Why?
|
| Gamma Rays | 1 | 1996 | 25 | 0.010 |
Why?
|
| Bacteremia | 1 | 1996 | 66 | 0.010 |
Why?
|